NCT05130177 2026-03-31
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
University of Pittsburgh
Phase 2 Active not recruiting
Clinical Trials
24 trialsNCT07397611 2026-03-20
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT06133517 2026-03-16
PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer
Fundación para el Progreso de la Oncología en Cantabria
Phase 2 Active not recruiting
NCT05824468 2026-03-10
Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer
Sun Yat-sen University
Phase 2 Active not recruiting
NCT05335941 2026-03-04
A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07424664 2026-02-20
A Single-arm, Multicenter Clinical Study of Becotatug Vedotin Combined With Zimberelimab in the Treatment of Recurrent and Metastatic Cervical Cancer, Vulvar Cancer and Vaginal Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Not yet recruiting
NCT06048133 2026-01-23
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
Big Ten Cancer Research Consortium
Phase 2 Recruiting
NCT07134556 2026-01-23
ADJUNCT
MedSIR
Phase 2 Not yet recruiting
NCT07337447 2026-01-13
REWENEC 01
Hospices Civils de Lyon
Phase 2 Not yet recruiting
NCT07283848 2025-12-26
Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma
Massachusetts General Hospital
Phase 2 Withdrawn
NCT04791839 2025-11-05
Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer
Washington University School of Medicine
Phase 2 Active not recruiting
NCT05886634 2025-10-20
A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT06790706 2025-10-06
IMMUNORARE5
Hospices Civils de Lyon
Phase 2 Recruiting
NCT05024097 2025-08-27
PANTHER
Weill Medical College of Cornell University
Phase 2 Recruiting
NCT05632848 2025-07-21
Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer Patients
Sun Yat-sen University
Phase 2 Completed
NCT05724563 2025-05-21
Domvanalimab and Zimberelimab in Advanced Liver Cancers
University of Texas Southwestern Medical Center
Phase 2 Active not recruiting
NCT05915442 2025-05-20
SBRT-AMICO
Columbia University
Phase 2 Recruiting
NCT06528483 2024-07-30
preSAVE
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Not yet recruiting
NCT06166589 2023-12-12
Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT06128460 2023-11-30
Adjuvant Chemoradiotherapy Followed by Zimberelimab for Locally Advanced Cervical Cancer.
Obstetrics & Gynecology Hospital of Fudan University
Phase 2 Not yet recruiting
NCT06107114 2023-11-22
CZCNRHNSCC
Sun Yat-sen University
Phase 2 Unknown
NCT06055738 2023-09-28
Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC
Tang-Du Hospital
Phase 2 Recruiting
NCT06009029 2023-08-24
SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)
Peking University Third Hospital
Phase 2 Not yet recruiting
NCT05872724 2023-05-24
Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)
Suzhou Municipal Hospital
Phase 2 Recruiting